We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LITE:NASDAQLumentum Holdings Inc. Analysis

Data as of 2026-08-24 - not real-time

$866.71

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Lumentum Holdings Inc. trades at $866.71, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 8.1% over the past 30 days. RSI sits at 52.5, which reads as neutral, and MACD momentum is bullish. The recent range runs from support at $594.84 up to resistance at $999.67.
On valuation the read is fair — earnings multiple of 26.3 versus a 35.2 sector average, below the peer group. Consensus targets land 32.5% above where the shares trade now. Revenue is growing at 109.3% on a -230.1% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 111.8%, a beta of 3.00 and a maximum drawdown of 42.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 3/10 conviction over the longer horizon.

Top Market Events

Shares of optical technology leaders Lumentum Holdings Inc.Leadership transition and why it matters for Lumentum Holdings Lumentum Holdings LITE recently disclosed that Executive...12dLumentum beats estimates on AI demand, guides above consensus; shares jumpLumentum Holdings Inc NASDAQ:LITE reported...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 652.62
  • MACD momentum is positive

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 26.3 versus sector average of 35.2
  • Trading above the 200-day average of 652.62

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 26.3 versus sector average of 35.2
  • Negative profit margin of -230.1%
  • Analyst targets imply +32.5% versus the current price

Key Metrics & Analysis

Financial Health

Revenue Growth109.30%
Profit Margin-230.10%
P/E Ratio26.3
ROE-240.03%
ROA5.82%
Debt/Equity35.99
P/B Ratio16.5
Op. Cash Flow$751.4M
Free Cash Flow$224.7M
Industry P/E35.2

Technical Analysis

TrendBullish
RSI52.5
Support$594.84
Resistance$999.67
MA 20$817.31
MA 50$814.41
MA 200$652.62
MACDBullish
VolumeIncreasing
Fear & Greed Index94.41

Valuation

Fair Value$99.38
Target Price$1,148.30
Upside/Downside32.49%
GradeFair
TypeGrowth

Risk Assessment

Beta3.00
Volatility111.84%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.